Microencapsulated conjugated linoleic acid associated with hypocaloric diet reduces body fat in sedentary women with metabolic syndrome

Roberta F Carvalho, Sofia K Uehara, Glorimar Rosa, Roberta F Carvalho, Sofia K Uehara, Glorimar Rosa

Abstract

Background: Animal studies have suggested beneficial effects of conjugated linoleic acid (CLA) in reducing body fat mass and improvement in the serum lipid profile and glycemia. However, these effects are controversial in humans. The purpose of this study was to investigate the effects of microencapsulated CLA supplementation on body composition, body mass index, waist circumference, and blood pressure in sedentary women with metabolic syndrome.

Methods: This study was a placebo-controlled and randomized clinical trial. Fourteen women diagnosed with metabolic syndrome received light strawberry jam enriched or not with microencapsulated CLA (3 g/day) as a mixture of 38.57% cis-9, trans-11, and 39.76% trans-10, cis-12 CLA isomers associated with a hypocaloric diet for 90 days. The subjects were monitored to assess variables associated with the metabolic syndrome, in addition to assessing adherence with the intervention.

Results: There were no significant effects of microencapsulated CLA on the lipid profile or blood pressure. Mean plasma insulin concentrations were significantly lower in women supplemented with microencapsulated CLA (Δ T₉₀ - T₀ = -12.87 ± 4.26 μU/mL, P = 0.02). Microencapsulated CLA supplementation did not alter the waist circumference, but there was a reduction in body fat mass detected after 30 days (Δ = -2.68% ± 0.82%, P = 0.02), which was maintained until the 90-day intervention period (Δ = -3.32% ± 1.41%, P = 0.02) in the microencapsulated CLA group. The placebo group showed this effect only after 90 days (Δ = -1.97% ± 0.60%, P = 0.02), but had a reduced waist circumference (Δ T₉₀ - T₀ = -4.25 ± 1.31 cm, P = 0.03).

Conclusion: Supplementation with mixed-isomer microencapsulated CLA may have a favorable effect on glycemic control and body fat mass loss at an earlier time in sedentary women with metabolic syndrome, although there were no effects on lipid profile and blood pressure.

Keywords: body composition; cardiovascular disease; conjugated linoleic acid; metabolic syndrome.

Figures

Figure 1
Figure 1
Percentage change in body fat in subjects administered placebo or microencapsulated CLA during 90 days. Notes: Values are means with 95% confidence intervals (n = 14) and were measured at the same time points for all two groups (ie, day 0, 30, 60 and 90). Intervals not including 0 are significant in the CLA group and only at day 90 in the placebo group. Abbreviation: CLA, conjugated linoleic acid.

References

    1. Athyros VG, Ganotakis ES, Elisaf MS, Liberopoulos EN, Goudevenos IA, Karagiannis A. Prevalence of vascular disease in metabolic syndrome using three proposed definitions. Int J Cardiol. 2007;117:204–210.
    1. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–1645.
    1. National Cholesterol Education Program; National Heart, Lung and Blood Institute; National Institutes of Health. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Circulation. 2006;106:3143–3421.
    1. Yanagita T, Nagao K. Functional lipids and the prevention of the metabolic syndrome. Asia Pac J Clin Nutr. 2008;17(Suppl 1):189–191.
    1. Or-Rashid MM, Wright TC, McBride BW. Microbial fatty acid conversion within the rumen and the subsequent utilization of these fatty acids to improve the healthfulness of ruminant food products. Appl Microbiol Biotechnol. 2009;84:1033–1043.
    1. Churruca I, Fernández-Quintela A, Portillo MP. Conjugated linoleic acid isomers: differences in metabolism and biological effects. Biofactors. 2009;35:105–111.
    1. Taylor CG, Zahradka P. Dietary conjugated linoleic acid and insulin sensitivity and resistance in rodent models. Am J Clin Nutr. 2004;79(Suppl 6):S1164–1168.
    1. Lee JS, Song YB, Lee JY, Kim MK, Jun SJ, Lee HG. Optimization and oxidative stability of the microencapsulated conjugated linoleic acid. Int J Biol Macromol. 2009;45:348–351.
    1. Aminot-Gilchrist DV, Anderson HDI. Insulin resistance-associated cardiovascular disease: potential benefits of conjugated linoleic acid. Am J Clin Nutr. 2004;79(Suppl 6):S1159–1163.
    1. Pfeuffer M, Fielitz K, Laue C, et al. CLA does not impair endothelial function and decreases body weight as compared with safflower oil in overweight and obese male subjects. J Am Coll Nutr. 2011;30:19–28.
    1. Gaullier JM, Halse J, Høye K, et al. Supplementation with conjugated linoleic acid for 24 months is well tolerated by and reduces body fat mass in healthy, overweight humans. J Nutr. 2005;135:778–784.
    1. Risérus U, Arner P, Brismar K, Vessby B. Treatment with dietary trans10cis12 conjugated linoleic acid causes isomer-specific insulin resistance in obese men with the metabolic syndrome. Diabetes Care. 2002;25:1516–1521.
    1. Taylor JS, Williams SR, Rhys R, James P, Frenneaux MP. Conjugated linoleic acid impairs endothelial function. Arterioscler Thromb Vasc Biol. 2006;26:307–312.
    1. International Diabetes Federation. IDF Worldwide Definition of the Metabolic Syndrome. International Diabetes Federation. [serial on the Internet] 2005. [Accessed July 28, 2006]. .
    1. Brazilian Society of Cardiology. First Brazilian guidelines for diagnosis and treatment of metabolic syndrome. Arq Bras Cardiol. 2005;84(Suppl 1):3–28.
    1. Gomes VB, Siqueira KS, Sichieri R. Physical activity among a random sample of the Rio de Janeiro. Cad Saude Publica. 2001;17:969–976. Portuguese.
    1. Ainsworth BE, Haskell WL, Herrmann SD, et al. Compendium of Physical Activities: a second update of codes and MET values. Med Sci Sports Exerc. 2011;2011;43:1575–1581.
    1. Trinder R. Determination of glucose in blood using glucose with alternative oxygen acceptor. Ann Clin Biochem. 1969;6:24–27.
    1. Matthews DR, Hosker JP, Rudenski BA, Naylor DF, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419.
    1. Bucolo G, David H. Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem. 1973;19:476–482.
    1. Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem. 1974;20:470–475.
    1. Warnick GR, Nauck M, Rifai N. Evolution of methods for measurement of HDL-cholesterol: from ultracentrifugation to homogeneous assays. Clin Chem. 2001;47:1579–1596.
    1. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.
    1. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation. 2005;111:697–716.
    1. Heyward VH, Stolarczyk KM. Fundamentals of body composition. In: Heyward VH, Stolarczyk KM, editors. Body Composition Assessment Applied. São Paulo, Brazil: Manole; 2000.
    1. Gibson RS. Principles of Nutritional Assessment. 2nd ed. New York, NY: Oxford University Press Inc; 2005.
    1. World Health Organization. Obesity: Preventing and Managing the Global Epidemic: Report of a WHO Consultation on Obesity. Geneva, Switzerland: World Health Organization; 1998.
    1. World Health Organization. Measuring Obesity – Classification and Description of Anthropometric Data Report of a WHO Regional Office Consultation on the Epidemiology of Obesity. Copenhagen, Denmark: World Health Organization; 1988.
    1. Lambert EV, Goedecke JH, Bluett K, et al. Conjugated linoleic acid versus high-oleic acid sunflower oil: effects on energy metabolism, glucose tolerance, blood lipids, appetite and body composition in regularly exercising individuals. Br J Nutr. 2007;97:1001–1011.
    1. Raff M, Tholstrup T, Basu S, Nonboe P, Sørensen MT, Straarup EM. A diet rich in conjugated linoleic acid and butter increases lipid peroxidation but does not affect atherosclerotic, inflammatory, or diabetic risk markers in healthy young men. J Nutr. 2008;138:509–514.
    1. Brown AW, Trenkle AH, Beitz DC. Diets high in conjugated linoleic acid from pasture-fed cattle did not alter markers of health in young women. Nutr Res. 2011;31:33–41.
    1. Ingelsson E, Risérus U. Effects of trans10cis12CLA-induced insulin resistance on retinol-binding protein 4 concentrations in abdominally obese men. Diabetes Res Clin Pract. 2008;82:e23–e24.
    1. Iwata T, Kamegai T, Yamauchi-Sato Y, et al. Safety of dietary conjugated linoleic acid (CLA) in a 12-weeks trial in health overweight Japanese male volunteers. J Oleo Sci. 2007;56:517–525.
    1. Moloney F, Yeow TP, Mullen A, Nolan JJ, Roche HM. Conjugated linoleic acid supplementation, insulin sensitivity, and lipoprotein metabolism in patients with type 2 diabetes mellitus. Am J Clin Nutr. 2004;80:887–895.
    1. Joseph SV, Jacques H, Plourde M, Mitchell PL, McLeod RS, Jones PJ. Conjugated linoleic acid supplementation for 8 weeks does not affect body composition, lipid profile, or safety biomarkers in overweight, hyperlipidemic men. J Nutr. 2011;141:1286–1291.
    1. Laso N, Brugué E, Vidal J, et al. Effects of milk supplementation with conjugated linoleic acid (isomers cis-9, trans-11 and trans-10, cis-12) on body composition and metabolic syndrome components. Br J Nutr. 2007;98:860–867.
    1. Aryaeian N, Shahram F, Djalali M, et al. Effect of conjugated linoleic acid, vitamin E and their combination on lipid profiles and blood pressure of Iranian adults with active rheumatoid arthritis. Vasc Health Risk Manag. 2008;4:1423–1432.
    1. Racine NM, Watras AC, Carrel AL, et al. Effect of conjugated linoleic acid on body fat accretion in overweight or obese children. Am J Clin Nutr. 2010;91:1157–1164.
    1. Chen SC, Lin YH, Huang HP, Hsu WL, Houng JY, Huang CK. Effect of conjugated linoleic acid supplementation on weight loss and body fat composition in a Chinese population. Nutrition. 2012;28:559–565.
    1. Noone EJ, Roche HM, Nugent AP, Gibney MJ. The effect of dietary supplementation using isomeric blends of conjugated linoleic acid on lipid metabolism in healthy human subjects. Br J Nutr. 2002;88:243–251.
    1. Raff M, Tholstrup T, Sejrsen K, Straarup EM, Wiinberg N. Diets rich in conjugated linoleic acid and vaccenic acid have no effect on blood pressure and isobaric arterial elasticity in healthy young men. J Nutr. 2006;136:992–997.
    1. Sluijs I, Plantinga Y, de Roos B, Mennen LI, Bots ML. Dietary supplementation with cis-9, trans-11 conjugated linoleic acid and aortic stiffness in overweight and obese adults. Am J Clin Nutr. 2010;91:175–183.
    1. Zhao WS, Zhai JJ, Wang YH, et al. Conjugated linoleic acid supplementation enhances antihypertensive effect of ramipril in Chinese patients with obesity-related hypertension. Am J Hypertens. 2009;22:680–686.
    1. Gaullier JM, Halse J, Høivik HO, et al. Six months supplementation with conjugated linoleic acid induces regional-specific fat mass decreases in overweight and obese. Br J Nutr. 2007;97:550–560.
    1. Norris LE, Collene AL, Asp ML, et al. Comparison of dietary conjugated linoleic acid with safflower oil on body composition in obese postmenopausal women with type 2 diabetes mellitus. Am J Clin Nutr. 2009;90:468–476.
    1. Nazare JA, de la Perrière AB, Bonnet F, et al. Daily intake of conjugated linoleic acid-enriched yoghurts: effects on energy metabolism and adipose tissue gene expression in healthy subjects. Br J Nutr. 2007;97:273–280.
    1. Kennedy A, Chung S, LaPoint K, Fabiyi O, McIntosh MK. Trans-10, cis-12 conjugated linoleic acid antagonizes ligand-dependent PPARgamma activity in primary cultures of human adipocytes. J Nutr. 2008;138:455–461.
    1. Granlund L, Juvet LK, Pedersen JI, Nebb HI. Trans10, cis12-conjugated linoleic acid prevents triacylglycerol accumulation in adipocytes by acting as a PPAR gamma modulator. J Lipid Res. 2003;44:1441–1452.
    1. Amati L, Marzulli G, Martulli M, Chiloiro M, Jirillo E. Effects of a hypocaloric diet on obesity biomarkers: prevention of low-grade inflammation since childhood. Curr Pharm Des. 2010;16:893–897.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する